A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)
Not Applicable
- Conditions
- unresectable/advanced gastric cancer
- Registration Number
- JPRN-UMIN000016256
- Lead Sponsor
- Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1)With prior chemotherapy including oxaliplatin (L-OHP) 2)With some active double cancers 3)With severe complications 4)With active infectious diseases which need treatments 5)With thoracic fluid and/or ascites which need drainage 6)under continuous steroids medication 7)under medication of phenytoin and/or warfarin 8)with active bleeding which needs frequent blood transfusion 9)with central nerve metastases with symptoms 10) with psychological disorders 11) Pregnant and/or nursing women or men who like to have children 12)Any other patients whom the physician in charge of the study judges to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease Control Rate
- Secondary Outcome Measures
Name Time Method Overall Survival, Progression Free Survival, Time To Failure, Response Rate, Incidence of Adverse Events